Compare AbbVie Inc (ABBV) vs Toronto-Dominion Bank (TD) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

TD stock trades at $121.43, up 1.79% today, with a bullish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. Analysts maintain a buy consensus with a $153 price target, and the company recently increased its dividend.

The outlook is positive given strong profitability, dividend growth, and analyst support, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers value with a P/E of 20.1 and robust ROE of 12.59%, though investors should monitor credit performance amid economic softness.